|
1
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999.
|
|
2
|
Aljiffry M, Abdulelah A, Walsh M,
Peltekian K, Alwayn I and Molinari M: Evidence-based approach to
cholangiocarcinoma: a systematic review of the current literature.
J Am Coll Surg. 208:134–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zografos GN, Farfaras A, Zagouri F,
Chrysikos D and Karaliotas K: Cholangiocarcinoma: principles and
current trends. Hepatobiliary Pancreat Dis Int. 10:10–20. 2011.
View Article : Google Scholar
|
|
4
|
Kiesslich T, Wolkersdorfer G, Neureiter D,
Salmhofer H and Berr F: Photodynamic therapy for non-resectable
perihilar cholangiocarcinoma. Photochem Photobiol Sci. 8:23–30.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verslype C, Prenen H and Van Cutsem E: The
role of chemotherapy in biliary tract carcinoma. HPB (Oxford).
10:164–167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bailey JM, Singh PK and Hollingsworth MA:
Cancer metastasis facilitated by developmental pathways: Sonic
hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem.
102:829–839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fava G, Marzioni M, Benedetti A, Glaser S,
DeMorrow S, Francis H and Alpini G: Molecular pathology of biliary
tract cancers. Cancer Lett. 250:155–167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiedmann MW and Mossner J: Molecular
targeted therapy of biliary tract cancer - results of the first
clinical studies. Curr Drug Targets. 11:834–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neureiter D, Herold C and Ocker M:
Gastrointestinal cancer -only a deregulation of stem cell
differentiation? (Review). Int J Mol Med. 483–489. 2006.PubMed/NCBI
|
|
10
|
Brabletz T, Jung A, Spaderna S, Hlubek F
and Kirchner T: Opinion: migrating cancer stem cells - an
integrated concept of malignant tumour progression. Nat Rev Cancer.
5:744–749. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brabletz S, Schmalhofer O and Brabletz T:
Gastrointestinal stem cells in development and cancer. J Pathol.
217:307–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jopling C, Boue S and Izpisua Belmonte JC:
Dedifferentiation, transdifferentiation and reprogramming: three
routes to regeneration. Nat Rev Mol Cell Biol. 12:79–89. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003.
|
|
14
|
Todaro M, Francipane MG, Medema JP and
Stassi G: Colon cancer stem cells: promise of targeted therapy.
Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alison MR, Lim SM and Nicholson LJ: Cancer
stem cells: problems for therapy? J Pathol. 223:147–161. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: Prognostic significance of the cancer stem cell markers
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest.
27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shimada M, Sugimoto K, Iwahashi S,
Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is
a potential prognostic indicator in intrahepatic
cholangiocarcinoma. J Gastroenterol. 45:896–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang M, Xiao J, Shen M, et al: Isolation
and characterization of tumorigenic extrahepatic cholangiocarcinoma
cells with stem cell-like properties. Int J Cancer. 128:72–81.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagai K, Ishii H, Miyoshi N, et al:
Long-term culture following ES-like gene-induced reprogramming
elicits an aggressive phenotype in mutated cholangiocellular
carcinoma cells. Biochem Biophys Res Commun. 395:258–263. 2010.
View Article : Google Scholar
|
|
20
|
Kiesslich T, Alinger B, Wolkersdorfer GW,
Ocker M, Neureiter D and Berr F: Active Wnt signalling is
associated with low differentiation and high proliferation in human
biliary tract cancer in vitro and in vivo and is
sensitive to pharmacological inhibition. Int J Oncol. 36:49–58.
2010.PubMed/NCBI
|
|
21
|
Berman DM, Karhadkar SS, Maitra A, et al:
Widespread requirement for Hedgehog ligand stimulation in growth of
digestive tract tumours. Nature. 425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Radonic A, Thulke S, Mackay IM, Landt O,
Siegert W and Nitsche A: Guideline to reference gene selection for
quantitative real-time PCR. Biochem Biophys Res Commun.
313:856–862. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Neureiter D, Zopf S, Dimmler A, et al:
Different capabilities of morphological pattern formation and its
association with the expression of differentiation markers in a
xenograft model of human pancreatic cancer cell lines.
Pancreatology. 5:387–397. 2005. View Article : Google Scholar
|
|
24
|
Zopf S, Neureiter D, Bouralexis S, et al:
Differential response of p53 and p21 on HDAC inhibitor-mediated
apoptosis in HCT116 colon cancer cells in vitro and in
vivo. Int J Oncol. 31:1391–1402. 2007.PubMed/NCBI
|
|
25
|
Kemmerling R, Stintzing S, Muhlmann J,
Dietze O and Neureiter D: Primary testicular lymphoma: A strictly
homogeneous hematological disease? Oncol Rep. 23:1261–1267.
2010.PubMed/NCBI
|
|
26
|
Tannapfel A and Wittekind C: The current
TNM system for gastrointestinal tumors part II. Pathologe.
31:348–352. 2010.(In German).
|
|
27
|
Malhi H and Gores GJ: Cholangiocarcinoma:
modern advances in understanding a deadly old disease. J Hepatol.
45:856–867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimada M, Sugimoto K, Iwahashi S,
Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is
a potential prognostic indicator in intrahepatic
cholangiocarcinoma. J Gastroenterol. 45:896–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang C, Fu X, Chen P, et al:
Dedifferentiation derived cells exhibit phenotypic and functional
characteristics of epidermal stem cells. J Cell Mol Med.
14:1135–1145. 2010.PubMed/NCBI
|
|
31
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: an emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sasaki M, Yamaguchi J, Ikeda H, Itatsu K
and Nakanuma Y: Polycomb group protein Bmi1 is overexpressed and
essential in anchorage-independent colony formation, cell
proliferation and repression of cellular senescence in
cholangiocarcinoma: tissue and culture studies. Hum Pathol.
40:1723–1730. 2009. View Article : Google Scholar
|
|
33
|
Horst D, Kriegl L, Engel J, Jung A and
Kirchner T: CD133 and nuclear beta-catenin: the marker combination
to detect high risk cases of low stage colorectal cancer. Eur J
Cancer. 45:2034–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miller G, Socci ND, Dhall D, et al: Genome
wide analysis and clinical correlation of chromosomal and
transcriptional mutations in cancers of the biliary tract. J Exp
Clin Cancer Res. 28:622009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jarnagin WR, Klimstra DS, Hezel M, et al:
Differential cell cycle-regulatory protein expression in biliary
tract adenocarcinoma: correlation with anatomic site, pathologic
variables, and clinical outcome. J Clin Oncol. 24:1152–1160. 2006.
View Article : Google Scholar
|
|
36
|
Karamitopoulou E, Tornillo L, Zlobec I, et
al: Clinical significance of cell cycle- and apoptosis-related
markers in biliary tract cancer: a tissue microarray-based approach
revealing a distinctive immunophenotype for intrahepatic and
extrahepatic cholangiocarcinomas. Am J Clin Pathol. 130:780–786.
2008. View Article : Google Scholar
|
|
37
|
Ohtsubo I, Ajiki T, Hori Y, et al:
Distinctive expression of CD133 between intraductal papillary
neoplasms of the bile duct and bile duct adenocarcinomas. Hepatol
Res. Jan 6–2012.(Epub ahead of print).
|
|
38
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kiesslich T, Berr F, Alinger B, Kemmerling
R, Pichler M, Ocker M and Neureiter D: Current status of
therapeutic targeting of developmental signalling pathways in
oncology. Curr Pharm Biotechnol. May 24–2011.(Epub ahead of
print).
|
|
40
|
Dalerba P, Dylla SJ, Park IK, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Quint K, Stintzing S, Alinger B, et al:
The expression pattern of PDX-1, SHH, patched and Gli-1 is
associated with pathological and clinical features in human
pancreatic cancer. Pancreatology. 9:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li L and Clevers H: Coexistence of
quiescent and active adult stem cells in mammals. Science.
327:542–545. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Scoville DH, Sato T, He XC and Li L:
Current view: intestinal stem cells and signaling.
Gastroenterology. 134:849–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gillet JP, Calcagno AM, Varma S, et al:
Redefining the relevance of established cancer cell lines to the
study of mechanisms of clinical anti-cancer drug resistance. Proc
Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kiesslich T and Neureiter D: Editorial:
Advances in targeting the hedgehog signaling pathwy in cancer
therapy. Expert Opin Ther Targets. 16:151–156. 2012. View Article : Google Scholar
|
|
46
|
Matsuoka J, Yashiro M, Sakurai K, et al:
Role of the stemness factors Sox2, Oct3/4, and Nanog in gastric
carcinoma. J Surg Res. 130–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Yu H, Yang Y, et al: SOX2 in
gastric carcinoma, but not Hath1, is related to patients’
clinicopathological features and prognosis. J Gastrointest Surg.
14:1220–1226. 2010.PubMed/NCBI
|
|
48
|
Lin T, Ding YQ and Li JM: Overexpression
of Nanog protein is associated with poor prognosis in gastric
adenocarcinoma. Med Oncol. Feb 20–2011.(Epub ahead of print).
|
|
49
|
Liu JH, Song LB, Zhang X, et al: Bmi-1
expression predicts prognosis for patients with gastric carcinoma.
J Surg Oncol. 97:267–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Saiki Y, Ishimaru S, Mimori K, et al:
Comprehensive analysis of the clinical significance of inducing
pluripotent stemness-related gene expression in colorectal cancer
cells. Ann Surg Oncol. 16:2638–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang H, Pan K, Zhang HK, et al: Increased
polycomb-group oncogene Bmi-1 expression correlates with poor
prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol.
134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Q, He W, Lu C, et al: Oct3/4 and Sox2
are significantly associated with an unfavorable clinical outcome
in human esophageal squamous cell carcinoma. Anticancer Res.
29:1233–1241. 2009.PubMed/NCBI
|
|
53
|
Lengerke C, Fehm T, Kurth R, et al:
Expression of the embryonic stem cell marker SOX2 in early-stage
breast carcinoma. BMC Cancer. 11:422011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vrzalikova K, Skarda J, Ehrmann J, et al:
Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients:
a tissue microarray study. J Cancer Res Clin Oncol. 134:1037–1042.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hayry V, Tynninen O, Haapasalo HK, et al:
Stem cell protein BMI-1 is an independent marker for poor prognosis
in oligodendroglial tumours. Neuropathol Appl Neurobiol.
34:555–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shi CJ, Gao J, Wang M, et al: CD133(+)
gallbladder carcinoma cells exhibit self-renewal ability and
tumorigenicity. World J Gastroenterol. 17:2965–2971. 2011.
|
|
57
|
Shi C, Tian R, Wang M, et al:
CD44+ CD133+ population exhibits cancer stem
cell-like characteristics in human gall-bladder carcinoma. Cancer
Biol Ther. 10:1182–1190. 2010.
|
